Year 1: 899,997.00 Year 2: 900.003.00
Pure Protein, L.L.C.: EDGE-Enabled Expansion of Protein-Based Transplantation Products
Pure Protein, L.L.C.
A patient who receives a heart or kidney transplant will often develop antibodies against the transplanted organ. These “anti-HLA” antibodies are responsible for transplant rejection and organ failure. To prevent rejection, transplant recipients must take immunosuppressive drugs that nearly eliminate the immune system. This puts transplant recipients at high risk for infections and cancer. Researchers at the University of Oklahoma Health Sciences Center (OUHSC) and the Oklahoma-based biotechnology company Pure Protein have developed a proprietary method for removing these anti-HLA antibodies, providing a strategy that could prevent the rejection of transplanted organs.